Moderna (MRNA)

by | Dec 4, 2020 | Daily Trade Alert

On Oct. 23, we highlighted opportunity in Moderna (MRNA) at $72.40. Today, it’s up to $157.26 good for a return of 117%. But the run is far from over. In fact, we could see it closer to $200 a share in the next two weeks. All as the company’s expects an emergency use nod for its vaccine shortly after its Dec. 17 meeting with the US FDA.

According to the company, it’s in a position to ramp up production quickly and could generate a good chunk of cash next year with it.

“Moderna, which is one of the front-runners in the race to develop a coronavirus vaccine, has applied for emergency authorizations both in the United States and the EU after full results from a late-stage study showed its vaccine was 94.1% effective with no serious safety concerns,” reports Reuters.

Related Content